Fortitude Biomedicines, Inc.

Based in the US, Fortitude Biomedicines develops innovative biopharmaceutical products to address critical unmet medical needs, focusing on therapeutics for oncology and rare diseases. Fortitude Biomedicines is focused on creating biopharmaceutical solutions to meet pressing medical requirements. The company was founded in 2025 in Waltham, US. In January 2026, Fortitude raised USD 13.

00 mn in Seed funding from investors including K2VC and Shanghai Healthcare Capital. The company has completed 1 deal to date, which supports its ongoing business operations. Fortitude Bio specializes in developing innovative biopharmaceutical products aimed at addressing critical unmet medical needs. Their core offerings include a range of therapeutics designed to improve patient outcomes in various therapeutic areas, such as oncology and rare diseases.

These products leverage advanced scientific research and technology to enhance the efficacy and safety of treatments, effectively targeting disease mechanisms at the molecular level. The company primarily serves healthcare institutions, including hospitals and specialty clinics, as well as pharmaceutical distributors. Fortitude Bio's products have been released into markets across North America, Europe, and select regions in Asia, catering to a diverse patient population and healthcare professionals dedicated to delivering comprehensive medical care. Fortitude Bio generates revenue through a combination of direct sales and strategic partnerships within the healthcare landscape.

The company structures its transactions primarily through business-to-business (B2B) channels, collaborating with healthcare providers and pharmaceutical wholesalers to distribute its products effectively. Revenue is driven by the sales of flagship therapeutics, which are typically offered under subscription models or through negotiated contracts with healthcare providers. These agreements may involve tiered pricing based on volume or specific treatment requirements, creating a reliable revenue stream as products gain traction in the market. The company's ability to establish long-term partnerships with key stakeholders in the healthcare sector is essential to its ongoing financial performance and market presence.

Fortitude Biomedicines plans to utilize its recent Seed funding of USD 13. 00 mn raised in January 2026 to advance its lead immune cell targeting biologic through IND-enabling studies and support the development of its GLUE-DAC platform. The company is also targeting expansion into new markets within Asia and Europe, aiming for broader market penetration by the end of 2026.